TABLE 1 

RTS,S malaria vaccine and mortality by sex

Sex and age of groupNo. of deaths overall [no. of deaths due to malaria]/no. of persons in group (%)RTS,S recipient/control risk ratio (95% CI)
R3RaR3CbR3R and R3C groups combinedC3Cc
Males
    5–17 mo26 [4]/1,509 (1.7)19 [9]/1,472 (1.3)45 [13]/2,981 (1.5)29 [8]/1,471 (2.0)0.77 (0.48–1.22)
    6–12 wk24 [3]/1,116 (2.2)26 [8]/1,118 (2.3)50 [11]/2,234 (2.2)26 [3]/1,079 (2.4)0.93 (0.58–1.48)
 
    Total95 [24]/5,215 (1.8)55 [11]/2,550 (2.2)0.84 (0.61–1.17)
 
Females
    5–17 mo35 [9]/1,467 (2.4)32 [8]/1,500 (2.1)67 [17]/2,967 (2.3)17 [4]/1,503 (1.1)2.00 (1.18–3.39)
    6–12 wk27 [5]/1,064 (2.5)29 [4]/1,060 (2.7)56 [9]/2,124 (2.6)16 [3]/1,100 (1.5)1.81 (1.04–3.14)
 
    Total123 [26]/5,091 (2.4)33 [7]/2,603 (1.3)1.91 (1.30–2.79)
  • a R3R, 3× RTS,S plus booster RTS,S.

  • b R3C, 3× RTS,S plus comparator vaccine.

  • c C3C, controls (comparator vaccines).